Mindrank AI raised $52 million in a Series B round to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist in phase III development for obesity in China. The financing supports scaling its Molecule Arts Platform and progressing multiple clinical and preclinical programs following MDR-001’s progression to late-stage trials.